Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 8/20 | 0.41 |
| ▸ | HTR1E | P28566 | 3/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177363 | 0.94 | PTGES (0.40) | PTGESHTR1ES1PR3MEN1LMNA | |
| SCHEMBL3701718 | 0.93 | PTGES (0.40) | PTGESHTR1ES1PR3MEN1LMNA | |
| SCHEMBL1178131 | 0.88 | PTGES (0.42) | PTGESHTR1ES1PR3MEN1LMNA | |
| SCHEMBL1195138 | 0.88 | PTGES (0.44) | PTGESHTR1ES1PR3MEN1LMNA | |
| SCHEMBL1193786 | 0.88 | PTGES (0.43) | PTGESHTR1ES1PR3MEN1LMNA | |
| SCHEMBL1178961 | 0.87 | PTGES (0.46) | PTGESHTR1ES1PR3MEN1LMNA | |
| SCHEMBL1193761 | 0.87 | PPARG (0.38) | KMT2AMAPTUBE2MDCUN1D1MAOB | |
| SCHEMBL12871724 | 0.87 | PTGES (0.41) | PTGESHTR1ES1PR3MEN1LMNA | |
| SCHEMBL3700366 | 0.87 | PTGES (0.42) | PTGESHTR1ES1PR3MEN1LMNA | |
| SCHEMBL3701720 | 0.86 | PTGES (0.41) | PTGESHTR1ES1PR3MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| WO-2009127338-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | OTC, PC, HCAR2 | PTGES 224/4885HTR1E 4408/4885S1PR3 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.